The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 123-127

  Wasa, Junji ^a   Sugiura, Hideshi ^b   Kozawa, Eiji ^a   Kohyama, Keishi ^b   Yamada, Kenji ^b   Taguchi, Osamu ^b,c  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Angiotensin II type 1 receptor antagonist; CV11974; Metastasis; Osteosarcoma

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CANDESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; LIVER METASTASIS; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; TUMOR VOLUME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; BENZIMIDAZOLES; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLES;

EID: 79851490472     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kaya M, Wada T, Kawaguchi S, Nagoya S, Yamashita T, Abe Y, Hiraga H, Isu K, Shindoh M, Higashino F, Okada F, Tada M, Yamawaki S and Ishii S: Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 86: 864-869, 2002. (Pubitemid 34271020)
2. Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Beattie EJ Jr. and Murphy ML: High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer 33: 1151-1163, 1974.
3. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
4. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
5. Borre M, Offersen BV, Nerstrom B and Overgaard J: Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78: 940-944, 1998. (Pubitemid 28430025)
6. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
7. Wang D, Chen L and Gao F: Correlation of tumor microvessel density with prognosis in osteogenic sarcoma. Zhonghua Bing Li Xue Za Zhi 26: 266-269, 1997.
8. Fujimoto Y, Sasaki T, Tsuchida A and Chayama K: Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495: 197-200, 2001. (Pubitemid 32397704)
9. +ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol 173: 315-323, 2002. (Pubitemid 34552460)
10. Nadal JA, Scicli GM, Carbini LA and Scicli AG: Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB. Am J Physiol Heart Circ Physiol 282: H739-748, 2002.
11. 2 in rat heart endothelial cells. Free Radic Biol Med 25: 891-897, 1998. (Pubitemid 28538554)
12. Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M, Misciglia N, Mavilia C, Vellei U, Villari D and Serio M: Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 10: 245-255, 1999. (Pubitemid 29068063)
13. Williams B, Baker AQ, Gallacher B and Lodwick D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25: 913-917, 1995.
14. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and Robertson JW: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352: 179-184, 1998.
15. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T and Imaizumi T: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112: 67-75, 2003. (Pubitemid 38056377)
16. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M and Majima M: Angiotensin type la receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26: 271-279, 2005. (Pubitemid 40253497)
17. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T and Hayakawa M: Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62: 4176-4179, 2002. (Pubitemid 34830392)
18. Mori S, Ueda T, Kuratsu S, Hosono N, Izawa K and Uchida A: Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 61: 148-152, 1995.
19. Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M and Hayakawa M: Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 67: 41-49, 2007. (Pubitemid 46013466)
20. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y and Murai M: Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 12: 2888-2893, 2006.
21. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S and Kikkawa F: Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 11: 2686-2694, 2005. (Pubitemid 40569470)
22. Rivet J, Mourah S, Murata H, Mounier N, Pisonero H, Mongiat-Artus P, Teillac P, Calvo F, Janin A and Dosquet C: VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer 112: 433-442, 2008.
23. Donnern T, Al-Shibli K, Al-Saad S, Delghandi MP, Busund LT and Bremnes RM: VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: inverse correlation between expression in tumor and stromal cells. Lung Cancer 63: 277-283, 2009.
24. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, Fukuda H, Nakano H, Abe S, Tateishi A, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y and Nakamura M: Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35: 1089-1093, 1999. (Pubitemid 29339192)
25. Dutour A, Monteil J, Paraf F, Charissoux JL, Kaletta C, Sauer B, Naujoks K and Rigaud M: Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 11: 311-319, 2005.
26. Miura S, Mii Y, Miyauchi Y, Ohgushi H, Morishita T, Hohnoki K, Aoki M, Tamai S and Konishi Y: Efficacy of slow-releasing anticancer drug delivery systems on transplantable osteosarcomas in rats. Jpn J Clin Oncol 25: 25-31, 1995.